Partners in Peptides, Delivering for your Patients
Our API model is built for flexibility, speed and trust, so your peptide program moves forward with confidence.
At AmbioPharm, we don’t just manufacture peptide APIs, we co-create solutions that support your goals and deliver for your patients. With our team of scientific and technical experts, we offer:
From early phase development to full scale commercial supply, our infrastructure adapts to your molecule, timeline and program goals.
Our US and Shanghai sites streamline synthesis and purification, reducing complexity and accelerating delivery.
Every project is assigned a dedicated manager backed by cross-functional teams ensuring alignment, transparency, and speed.
AmbioPharm has developed a unique business model designed to expedite peptide manufacturing. We can handle any scale project from small (gram quantities) to large commercial quantities (>100kg). By streamlining our chemical synthesis operations at the source where nearly all of the key raw materials are produced, we are able to save our partners cost-of-goods by passing on these savings to them.
We can perform solid-phase, solution-phase or hybrid peptide chemistry plus organic conjugations to proteins, toxoids, antifungals, KLH (Keyhole Limpet Hemocyanin, and PEG (Polyethylene Glycol).
Our peptide development services go from preclinical to commercial development through the entire process from scale up to process qualification to process validation prior to NDA (New Drug Application) with the Food and Drug Administration.
We follow cGMP (Current Good Manufacturing Process) guidelines required by the FDA for peptide manufacturing and both sites are successfully inspected by the US FDA. In addition to contract peptide API manufacturing, we can also produce peptide APIs for established commercial markets and non-GMP peptides for clinical research.
Each project is assigned a project manager committed to your project, giving it the attention required to meet your needs.
At the same time as the development process is underway, AmbioPharm develops analytical HPLC (High Performance Liquid Chromatography) methods and validation tools. These tools will monitor the process for side reactions, required purity standards, and limit any residual impurities in the product. Controlling the final API to ensure the required quality attributes, we will minimize process and degradation impurities. This affords formulators the maximum labeled drug shelf life under proper storage conditions.
AmbioPharm operates under 21 GMP manufacturing lines designed to support projects from early development through commercial supply. Our scalable infrastructure ensures reliable production capacity for custom peptide APIs, with flexibility to meet the evolving needs of pharmaceutical and biotechnology partners.
AmbioPharm was founded in 2005 and is one of the largest capacity peptide manufacturers in the world. With a US Headquarters and facilities in North Augusta, South Carolina, and Shanghai, China, we employ more than 500 chemists and industry professionals. In 2021, AmbioPharm established a larger European sales presence in order to better serve our European customers.
Our cGMP peptide manufacturing facilities in the US and China can handle any manufacturing scale required. We currently operate multiple manufacturing lines capable of sustaining campaigns from grams to 300 kg/year. For commercial products, we design dedicated facilities at even larger scales to meet current and future needs of our clients.
SETTING A NEW STANDARD
Have a Peptide project?
中文